Serum alpha-1-antitrypsin in patients with malignant tumors occurring in the oral region.
In the present study, we have examined the immunoreactive levels of alpha-1-antitrypsin (AAT) and trypsin-inhibitory capacity (TIC) in the serum of patients with malignant tumors occurring in the oral region. AAT in the MFH group showed significantly high (468 +/- 129 mg/dl, mean +/- SD (n = 4)) as compared to those of other types of sarcoma groups (236 +/- 28 mg/dl, (n = 5)) and healthy controls (226 +/- 36 mg/dl, (n = 75)) (p less than 0.05). Patients with squamous cell carcinoma (SCC) also had increased levels of AAT (269 +/- 35 mg/dl, (n = 18)), but there was no significant difference among other groups including healthy controls. TIC of patients with MFH was higher (2.29 +/- 0.42 IU/ml, (n = 4)) than in the SCC group (1.44 +/- 0.25 IU/ml, (n = 18)), other sarcoma groups 1.21 +/- 0.16 IU/ml, (n = 5)) and controls (1.55 +/- 0.15 IU/ml, (n = 75)). These data suggest that the elevation of AAT and TIC would be helpful in the diagnosis of MFH.